Interestingly, Wong et al. [84] provided data to support the notion that HSP90 inhibitors may be an effective therapy to treat aromatase inhibitor-resistant breast cancers and that improved efficacy can be achieved by combined use of a HSP90 inhibitor and an AKT inhibitor. This evidence concerns the gene AKT1 and breast cancer.